Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical company Clinigen reiterated its outlook for 2021 organic net revenue growth to be toward the lower end of its 5%-to-10% medium-term guidance range.
The company said trading in 2021 had been in-line with market expectations despite the ongoing impact of COVID-19.
'As previously stated, we expect growth to be more weighted to H2 than in previous years due to the impact of COVID-19 and the timing of shipments for Proleukin to key customers,' the company said.
At 10:04am: (LON:CLIN) Clinigen Group PLC share price was 0p at 683p